Identification of HIF1A as a therapeutic target during SARS-CoV-2-associated lung injury.

Summary

In murine SARS-CoV-2 models and genetic studies, alveolar Hif1a mediated protection and vadadustat improved outcomes. In a multicenter, double-blind phase II RCT (n=448), vadadustat reduced the estimated probability of severe lung injury at day 14 vs placebo, with a striking benefit among patients with baseline FiO2 ≥80%. Safety was similar, and HIF target gene induction confirmed on-target effects.

Key Findings

• Vadadustat improved outcomes in murine SARS-CoV-2 lung injury models and induced HIF target genes in patients.
• In the phase II RCT (n=448), the estimated probability of severe lung injury at day 14 was 13.3% with vadadustat vs 16.9% with placebo.
• Marked benefit in patients with baseline FiO2 ≥80% (12.1% vadadustat vs 79.1% placebo).
• Safety profiles were similar between groups under blinded monitoring.

Clinical Implications

HIF stabilizers like vadadustat may be considered for evaluation in severe hypoxic pneumonia; current data justify larger confirmatory trials and suggest stratifying by baseline hypoxemia severity.

Limitations

• Overall treatment effect on the primary endpoint was modest; subgroup findings may be underpowered and hypothesis-generating
• Phase II study not powered for mortality or long-term outcomes; external validation needed

Future Directions

Conduct adequately powered phase III trials in pathogen-associated lung injury with stratification by baseline hypoxemia; explore optimal dosing window and potential synergy with standard-of-care anti-inflammatory or antiviral therapies.